Correspondence 0001193125-24-092551 from Lexeo Therapeutics, Inc. (LXEO)
Lexeo Therapeutics, Inc.
Date: April 11, 2024 · CIK: 0001907108 · Accession: 0001193125-24-092551
AI Filing Summary & Sentiment
File numbers found in text: 333-278566
Show Raw Text
CORRESP 1 filename1.htm CORRESP April 11, 2024 VIA EDGAR U.S. Securities and Exchange Commission Office of Life Sciences Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attn: Tamika Sheppard Re: Lexeo Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-278566 Acceleration Request Requested Date: April 12, 2024 Requested Time: 4:30 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Lexeo Therapeutics, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-1 (File No. 333-278566) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Megan Baier at (312) 636-2073. Sincerely, LEXEO THERAPEUTICS, INC. /s/ Jenny R. Robertson Jenny R. Robertson Chief Business and Legal Officer cc: R. Nolan Townsend Lexeo Therapeutics, Inc. Megan J. Baier David G. Sharon Wilson Sonsini Goodrich & Rosati, P.C.